Hypocalcemia may worsen with the use of Prolia ®, especially in patients with severe renal impairment. In patients predisposed to hypocalcemia and disturbances of mineral metabolism, clinical ...

Amgen (NASDAQ:AMGN) announced new data supporting its FDA-approved osteoporosis therapy Prolia (Denosumab) on Monday, highlighting its potential against oral alendronate, a commonly-used medication to ...

The FINANCIAL — Amgen on October 9 announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia (denosumab) for ...

Findings showed treatment with Prolia significantly increased the risk of developing severe hypocalcemia compared with bisphosphonates, especially in patients with advanced CKD. In patients with ...

Please provide your email address to receive an email when new articles are posted on . The FDA is investigating the risk of severe hypocalcemia in patients on dialysis treated with the osteoporosis ...

THOUSAND OAKS, Calif., May 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S.

Severe hypocalcemia was found to be more common among patients with advanced chronic kidney disease with mineral and bone disorder who are taking Prolia for osteoporosis. The FDA has revised the ...

(Reuters) - Amgen Inc, the world's largest biotechnology company, said U.S. health regulators approved its Prolia injection for a new use as a treatment to increase bone mass in men with osteoporosis ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

SLM@lutheran-jamestown.org. Question: My new doctor says that my Prolia shot will be very expensive. When my previous physician gave me the shot it was covered in full. Why the difference in cost?